The 2nd Society of Hematological Oncology (SOHO) Italian three-day meeting brings together leading SOHO experts and Italian researchers in acute leukemias, MPNs, and MDS, with the aims of consolidating the Italian Hematology-SOHO partnership.

Highlights from this year’s SOHO Italy Annual Meeting include clinical updates on leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, lymphomas and other related malignancies.

SOHO Italy 2020

SOHO Italy 2020

The 2nd Society of Hematological Oncology (SOHO) Italian three-day meeting brings together leading SOHO experts and Italian researchers in acute leukemias, MPNs, and MDS, with the aims of consolidating the Italian Hematology-SOHO partnership.

Highlights from this year’s SOHO Italy Annual Meeting include clinical updates on leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, lymphomas and other related malignancies.

Evolving understanding of multiple myeloma 7:47
Evolving understanding of multiple myeloma
Claudio Cerchione • 6 Sep 2020
Novel approaches to PV and ET 3:42
Novel approaches to PV and ET
Alessandro Lucchesi • 28 Sep 2020
Impact of COVID-19 on CLL treatment in Italy 2:21
Impact of COVID-19 on CLL treatment in Italy
Antonio Cuneo • 23 Sep 2020
CLL: state of the art in Italy 4:25
CLL: state of the art in Italy
Antonio Cuneo • 24 Sep 2020
Unmet needs in follicular lymphoma 1:51
Unmet needs in follicular lymphoma
Stefano Luminari • 24 Sep 2020
Italian perspective: managing lymphoma 4:28
Italian perspective: managing lymphoma
Stefano Luminari • 21 Sep 2020
New insights in the biology of myeloproliferative neoplasms 5:06
New insights in the biology of myeloproliferative neoplasms
Anna Rita Migliaccio • 17 Sep 2020
Finding novel targets for myelofibrosis from animal models 3:19
Finding novel targets for myelofibrosis from animal models
Anna Rita Migliaccio • 9 Sep 2020
Genetic profiling of multiple myeloma in the novel agents era 5:35
Genetic profiling of multiple myeloma in the novel agents era
Niccolò Bolli • 17 Sep 2020
Evolving treatment landscape of DLBCL 2:34
Evolving treatment landscape of DLBCL
Gerardo Musuraca • 17 Sep 2020
MDS: state of the art in Europe 4:10
MDS: state of the art in Europe
Valeria Santini • 10 Sep 2020
Optimizing biological agents for ALL 2:42
Optimizing biological agents for ALL
Francesco Lanza • 17 Sep 2020
Italian perspective: managing DLBCL 2:19
Italian perspective: managing DLBCL
Gerardo Musuraca • 17 Sep 2020
Phase IV studies: Spanish experience 0:55
Phase IV studies: Spanish experience
Adolfo De La Fuente • 17 Sep 2020
Balancing efficacy and tolerability in multiple myeloma 3:12
Balancing efficacy and tolerability in multiple myeloma
Patrizia Tosi • 21 Sep 2020
Multiple myeloma: ADCs and BiTEs 3:06
Multiple myeloma: ADCs and BiTEs
Hans Lee • 18 Sep 2020
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals